SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.

[1]  J. Vauthey,et al.  APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases , 2017, Annals of surgery.

[2]  K. Shaw,et al.  Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer , 2017, PloS one.

[3]  P. Lønning,et al.  Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.

[4]  M. Makuuchi,et al.  Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. , 2016, Surgery.

[5]  G. Troncone,et al.  Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases , 2016, Journal of Clinical Pathology.

[6]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[7]  J. Vauthey,et al.  Meta‐analysis of KRAS mutations and survival after resection of colorectal liver metastases , 2015, The British journal of surgery.

[8]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[9]  R. Pai,et al.  Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer , 2015, Journal of Clinical Pathology.

[10]  J. Hardwick,et al.  A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer , 2015, Translational oncology.

[11]  M. Ladanyi,et al.  BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.

[12]  Chang Yu,et al.  Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer , 2014, Gut.

[13]  S. Lee,et al.  Comparative Genomic Analysis of Primary and Synchronous Metastatic Colorectal Cancers , 2014, PloS one.

[14]  M. Makuuchi,et al.  Discrepancy Between Recurrence-Free Survival and Overall Survival in Patients with Resectable Colorectal Liver Metastases: A Potential Surrogate Endpoint for Time to Surgical Failure , 2014, Annals of Surgical Oncology.

[15]  M. Washington,et al.  Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway , 2014, British Journal of Cancer.

[16]  H. Moses,et al.  The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.

[17]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[18]  Seung-Yong Jeong,et al.  Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.

[19]  D. Busam,et al.  SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. , 2013, Cancer research.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[21]  P. Dijke,et al.  TGF-β signalling and its role in cancer progression and metastasis , 2012, Cancer and Metastasis Reviews.

[22]  S. Curley,et al.  High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[24]  S. Curley,et al.  Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.

[25]  Steven A Curley,et al.  Three Hundred and One Consecutive Extended Right Hepatectomies: Evaluation of Outcome Based on Systematic Liver Volumetry , 2009, Annals of surgery.

[26]  M. Choti,et al.  Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients , 2009, Annals of surgery.

[27]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[29]  J. Vauthey,et al.  Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.

[30]  P. Tekkis,et al.  Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.

[31]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[32]  Jukka-Pekka Mecklin,et al.  SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer , 2005, Clinical Cancer Research.

[33]  Evelyne M. Loyer,et al.  Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.

[34]  H T Lynch,et al.  The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations , 2004, Journal of Medical Genetics.

[35]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[36]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[37]  J. Massagué,et al.  Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.

[38]  P. Crespo,et al.  Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits , 1994, Nature.

[39]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[40]  J. Weitz,et al.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.